AstraZeneca (AZN LN) Obesity pill helps patients lose 10.5% of body weight in trial after 26 weeks vs 0.6% with placebo

Newsquawk StaffPublished 8 Jun 2026, 20:37 UTCOn the live feed at 20:17 UTC — 1 more headline followed before this page went public

Newsquawk headlinesUTC

20:39

Yemen drone attack reported against Israel, according to Fars

20:18

FedEx (FDX) raises annual dividend 5% after adjusting for FedEx Freight spin-off

20:17

AstraZeneca (AZN LN) Obesity pill helps patients lose 10.5% of body weight in trial after 26 weeks vs 0.6% with placebo

20:14

Newsquawk US Market Wrap - 8th June 2026: Tech rebounds and oil pares overnight gains as Trump pushes de-escalation

20:11

No agreement can be reached unless its frozen funds are released and sanctions are lifted, Al Jazeera reports citing an Iranian official

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio
Aadults with obesity or overweight and at least one comorbidity receiving elecoglipron (75mg) achieved a clinically meaningful and statistically significant average reduction in body weight of 10.5% at 26 weeks compared to 0.6% with placebo, a dual primary endpoint.
Weight loss in participants receiving elecoglipron did not plateau, reaching 11.8% at 36 weeks (75mg) versus 0.3% with placebo.
The trial also met the dual primary endpoint of proportion of participants achieving at least 5% weight loss at 26 weeks, with up to 88.8% of participants receiving elecoglipron achieving this threshold.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/8 Sept · 11:48 UTC

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations.

Market, after we published+1.0%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.